Drug-induced liver injury: The dawn of biomarkers?

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Weiler, Stefan ^a   Merz, Michael ^b   Kullak Ublick, Gerd A ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; ANABOLIC AGENT; BIOLOGICAL MARKER; CARBAMAZEPINE; CIPROFLOXACIN; CLINDAMYCIN; CLOPIDOGREL; COTRIMOXAZOLE; ENALAPRIL; ERYTHROMYCIN; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; ISONIAZID; KETOCONAZOLE; LISINOPRIL; LOSARTAN; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENYTOIN; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ARTICLE; CLINICAL PRACTICE; DOSE RESPONSE; HUMAN; LIVER INJURY; METABOLOMICS; NEXT GENERATION SEQUENCING; PATIENT SAFETY; PHARMACOGENETICS; PHYSICIAN; PROTEOMICS; TOXIC HEPATITIS; TREATMENT WITHDRAWAL;

EID: 84924529889     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-34     Document Type: Article

References (35)

1. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwakar JA; DILIN Network: Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014, 147:96-108.
2. Livertox: Clinical and Research Information on Drug-Induced Liver Injury. [http://www.livertox.nih.gov/]
3. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ; Practice Parameters Committee of the American College of Gastroenterology: ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014, 109:950-66.
4. Leise MD, Poterucha JJ, Talwalkar JA: Drug-induced liver injury. Mayo Clin Proc 2014, 89:95-106.
5. Danan G, Benichou C: Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries. J Clin Epidemiol 1993, 46:1323-30.
6. Benichou C, Danan G, Flahault A: Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 46:1331-6.
7. Maria VA, Victorino RM: Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997, 26:664-9.
8. News Release: Newcastle University leading project on drug induced liver disease. [http://www.ncl.ac.uk/numed/about/news/item/ newcastle-university-leading-project-on-drug-induced-liver-diseasecopy]
9. Russmann S, Jetter A, Kullak-Ublick GA: Pharmacogenetics of druginduced liver injury. Hepatology 2010, 52:748-61.
10. Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, Alfirevic A, Cederbrant K, Daly AK, French N, Pirmohamed M, Park BK, Naisbitt DJ: Human leukocyte antigen (HLA)-B 57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013, 57: 727-39.
11. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP; DILIGEN Study; International SAE Consortium: HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-9.
12. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT: Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet 2002, 359:727-32.
13. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team: HLA-B 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-79.
14. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP: Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclavinduced liver injury. J Hepatol 2010, 53:1049-53.
15. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA: A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010, 42:711-4.
16. Grove JI, Aithal GP: Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert Opin Drug Metab Toxicol 2014, 10:1-15. [Epub ahead of print].
17. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR: HLADQA1 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011, 29:667-73.
18. Kullak-Ublick GA, Merz M, Griffel L, Kaplowitz N, Watkins PB: Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf 2014, 37:57-62.
19. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerström-Fermér ME, Dellsén A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel TH, Billing-Clason SM, Cardon LR, March RE: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008, 8:186-95.
20. Andersson U, Lindberg J, Wang S, Balasubramanian R, Marcusson-Ståhl M, Hannula M, Zeng C, Juhasz PJ, Kolmert J, Bäckström J, Nord L, Nilsson K, Martin S, Glinghammar B, Cederbrant K, Schuppe-Koistinen I: A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers 2009, 14:572-86.
21. Innovative medicines initiative: SAFE-T. [http://www.imi.europa. eu/content/safe-t]
22. U.S. Food and Drug Administration: Predictive Safety Testing Consortium (PSTC). [http://www.fda.gov/AboutFDA/Partnerships Collaborations/PublicPrivatePartnershipProgram/ucm231132.htm]
23. Critical path institute: Predictive Safety Testing Consortium. [http://c-path.org/programs/pstc/pstc-tools/?anchor=section-582# section-582]
24. Temple R: Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006, 15:241-3.
25. Navarro VJ, Senior JR: Drug-related hepatotoxicity. N Engl J Med 2006, 354:731-9.
26. Senior JR: Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf 2014, 37(Suppl 1):S9-17.
27. Fontana RJ: Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014, 146:914-28.
28. Wang XW, Heegaard NH, Orum H: MicroRNAs in liver disease. Gastroenterology. 2012, 142:1431-43.
29. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G: Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012, 56:1946-57.
30. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK: Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011, 54:1767-76.
31. Antoine DJ, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, Craig DG, Simpson KJ, Jaeschke H, Park BK: Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol 2012, 56:1070-1079.
32. Thulin P, Nordahl G, Gry M, Yimer G, Aklillu E, Makonnen E, Aderaye G, Lindquist L, Mattsson CM, Ekblom B, Antoine DJ, Park BK, Linder S, Harrill AH, Watkins PB, Glinghammar B, Schuppe-Koistinen I: Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int 2013, [Epub ahead of print].
33. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN, Goldring CE, Park BK: Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013, 58:777-87.
34. McGill MR, Staggs VS, Sharpe MR, Lee WM, Jaeschke H; Acute Liver Failure Study Group: Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology 2014, 60:1336-45.
35. Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, Semple R, Weber A, Lomas DA, Vallier L: Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010, 120:3127-36.